Neurocrine Gross Profit from 2010 to 2025

NBIX Stock

USD 117.59 1.69 1.46%

Neurocrine Biosciences Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Neurocrine Biosciences makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

1996-03-31

Previous Quarter

614.1 M

Current Value

618.4 M

Quarterly Volatility

154.2 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 7.4 M or Selling General Administrative of 1.1 B, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.

Check out the analysis of Neurocrine Biosciences Correlation against competitors.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Neurocrine Biosciences over the last few years. Gross profit is a required income statement account that reflects total revenue of Neurocrine Biosciences minus its cost of goods sold. It is profit before Neurocrine Biosciences operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Neurocrine Biosciences' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.59 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Neurocrine Gross Profit Regression Statistics

	Arithmetic Mean	736,751,812
	Coefficient Of Variation	118.20
	Mean Deviation	731,250,289
	Median	446,351,000
	Standard Deviation	870,819,332
	Sample Variance	758326.3T
	Range	2.5B
	R-Value	0.92
	Mean Square Error	130809T
	R-Squared	0.84
	Slope	167,539,013
	Total Sum of Squares	11374894.6T

Neurocrine Gross Profit History

	2025	2.4 B
	2024	2.3 B
	2023	1.8 B
	2022	1.5 B
	2021	1.1 B
	2020	1 B
	2019	780.7 M

Other Fundumenentals of Neurocrine Biosciences

Gross Profit Margin

Neurocrine Biosciences Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Long Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.99	0.47	0.62	0.99	0.98	0.97	0.99	0.58	0.87	0.94	0.77	0.58	0.89	0.83	0.96	0.83	0.54	0.98	-0.8	0.74	-0.73	0.83	0.92
Total Stockholder Equity	0.99		0.42	0.67	0.98	0.99	0.93	0.97	0.54	0.86	0.92	0.7	0.55	0.86	0.86	0.98	0.8	0.5	0.97	-0.84	0.73	-0.72	0.86	0.93
Net Debt	0.47	0.42		0.13	0.5	0.47	0.56	0.49	0.76	0.22	0.48	0.6	0.25	0.48	0.41	0.32	0.44	0.34	0.55	0.05	0.23	-0.24	0.14	0.28
Retained Earnings	0.62	0.67	0.13		0.67	0.7	0.48	0.54	0.18	0.57	0.45	0.13	-0.14	0.46	0.75	0.64	0.24	0.26	0.6	-0.74	0.52	-0.38	0.67	0.71
Accounts Payable	0.99	0.98	0.5	0.67		0.99	0.95	0.97	0.65	0.85	0.92	0.72	0.52	0.88	0.84	0.93	0.79	0.53	0.97	-0.76	0.75	-0.66	0.8	0.89
Net Receivables	0.98	0.99	0.47	0.7	0.99		0.92	0.97	0.59	0.84	0.92	0.67	0.51	0.85	0.9	0.96	0.77	0.49	0.95	-0.8	0.69	-0.68	0.84	0.91
Total Liab	0.97	0.93	0.56	0.48	0.95	0.92		0.97	0.66	0.84	0.94	0.89	0.61	0.92	0.72	0.89	0.86	0.61	0.96	-0.68	0.73	-0.73	0.74	0.85
Total Current Assets	0.99	0.97	0.49	0.54	0.97	0.97	0.97		0.62	0.87	0.97	0.82	0.64	0.92	0.81	0.96	0.88	0.58	0.95	-0.75	0.66	-0.76	0.82	0.88
Short Term Debt	0.58	0.54	0.76	0.18	0.65	0.59	0.66	0.62		0.4	0.68	0.65	0.38	0.6	0.42	0.41	0.55	0.43	0.58	-0.08	0.33	-0.17	0.18	0.42
Intangible Assets	0.87	0.86	0.22	0.57	0.85	0.84	0.84	0.87	0.4		0.81	0.68	0.52	0.91	0.66	0.9	0.75	0.66	0.8	-0.79	0.62	-0.79	0.8	0.83
Short Term Investments	0.94	0.92	0.48	0.45	0.92	0.92	0.94	0.97	0.68	0.81		0.82	0.66	0.89	0.75	0.89	0.87	0.6	0.88	-0.66	0.61	-0.75	0.76	0.81
Long Term Debt	0.77	0.7	0.6	0.13	0.72	0.67	0.89	0.82	0.65	0.68	0.82		0.65	0.85	0.43	0.68	0.84	0.64	0.76	-0.4	0.49	-0.69	0.52	0.6
Common Stock	0.58	0.55	0.25	-0.14	0.52	0.51	0.61	0.64	0.38	0.52	0.66	0.65		0.61	0.3	0.59	0.88	0.46	0.55	-0.33	0.48	-0.57	0.54	0.51
Property Plant Equipment	0.89	0.86	0.48	0.46	0.88	0.85	0.92	0.92	0.6	0.91	0.89	0.85	0.61		0.6	0.88	0.88	0.71	0.85	-0.62	0.61	-0.8	0.72	0.77
Current Deferred Revenue	0.83	0.86	0.41	0.75	0.84	0.9	0.72	0.81	0.42	0.66	0.75	0.43	0.3	0.6		0.83	0.55	0.29	0.8	-0.75	0.48	-0.55	0.81	0.79
Net Tangible Assets	0.96	0.98	0.32	0.64	0.93	0.96	0.89	0.96	0.41	0.9	0.89	0.68	0.59	0.88	0.83		0.82	0.5	0.92	-0.88	0.66	-0.79	0.9	0.92
Capital Surpluse	0.83	0.8	0.44	0.24	0.79	0.77	0.86	0.88	0.55	0.75	0.87	0.84	0.88	0.88	0.55	0.82		0.66	0.8	-0.54	0.63	-0.74	0.74	0.74
Deferred Long Term Liab	0.54	0.5	0.34	0.26	0.53	0.49	0.61	0.58	0.43	0.66	0.6	0.64	0.46	0.71	0.29	0.5	0.66		0.49	-0.28	0.47	-0.61	0.51	0.49
Long Term Investments	0.98	0.97	0.55	0.6	0.97	0.95	0.96	0.95	0.58	0.8	0.88	0.76	0.55	0.85	0.8	0.92	0.8	0.49		-0.74	0.79	-0.68	0.78	0.87
Long Term Debt Total	-0.8	-0.84	0.05	-0.74	-0.76	-0.8	-0.68	-0.75	-0.08	-0.79	-0.66	-0.4	-0.33	-0.62	-0.75	-0.88	-0.54	-0.28	-0.74		-0.6	0.63	-0.86	-0.89
Net Invested Capital	0.74	0.73	0.23	0.52	0.75	0.69	0.73	0.66	0.33	0.62	0.61	0.49	0.48	0.61	0.48	0.66	0.63	0.47	0.79	-0.6		-0.53	0.68	0.75
Short Long Term Debt	-0.73	-0.72	-0.24	-0.38	-0.66	-0.68	-0.73	-0.76	-0.17	-0.79	-0.75	-0.69	-0.57	-0.8	-0.55	-0.79	-0.74	-0.61	-0.68	0.63	-0.53		-0.82	-0.68
Net Working Capital	0.83	0.86	0.14	0.67	0.8	0.84	0.74	0.82	0.18	0.8	0.76	0.52	0.54	0.72	0.81	0.9	0.74	0.51	0.78	-0.86	0.68	-0.82		0.89
Capital Stock	0.92	0.93	0.28	0.71	0.89	0.91	0.85	0.88	0.42	0.83	0.81	0.6	0.51	0.77	0.79	0.92	0.74	0.49	0.87	-0.89	0.75	-0.68	0.89

Click cells to compare fundamentals

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	2.3 B	2.4 B
Gross Profit Margin	0.99	1.03

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC